OQROGet OQRO Pro
Insider trade

Amgen (AMGN)SVP & CCO sold ~$376K

Nancy A. Grygiel, SVP & CCO at Amgen, sold ~$376K of Amgen shares.

~$376K
Approx. value · 1,267 sh @ $296.99
7,209
Holds after · shares reported
Traded
Aug 20, 2025
Filed
Aug 22, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Aug 7, 2024CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  2. Feb 11, 2025CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  3. May 12, 2025CongressDisclosed sale of AMGN — reported range $15,001 - $50,000
  4. Jun 6, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  5. Jun 24, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  6. Jul 23, 2025FDAFDA drug approval: Otezla
  7. Aug 20, 2025 · this disclosureInsiderOfficer sold ~$376K of AMGN shares in the open market

What came next

  1. Aug 29, 2025FDAFDA drug approval: Otezla
  2. Aug 29, 2025FDAFDA drug approval: Otezla
  3. Sep 4, 2025CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  4. Sep 8, 20255% stakeThe Vanguard Group reported a passive stake (13G) of 10.0%
  5. Sep 11, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  6. Sep 25, 2025CongressDisclosed sale of AMGN — reported range $1,001 - $15,000
  7. Oct 24, 2025CongressDisclosed purchase of AMGN — reported range $1,001 - $15,000
  8. Nov 4, 2025Company filing · Form 8-K · ResultsReported its results
  9. Nov 12, 2025Insider · 2 peopleInsiders: 2 sales (~$2.6M)
  10. Nov 19, 2025FDAFDA drug approval: Imdelltra
  11. Nov 20, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
  12. Dec 3, 2025Congress · 1 personMembers of Congress: 2 sales
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Amgen

For Amgen, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 5 Congress trade reports and 75 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AMGN page.

Other recent filings by Nancy A. Grygiel, SVP & CCO

The full history of Nancy A. Grygiel, SVP & CCO is on the profile page.

How this filing works

Other disclosures at Amgen

Everything OQRO holds on this company is on its AMGN page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data